Jul 22, 2020   SOURCE: PR NewsWire

Global Viral Vector & Plasmid DNA Manufacturing Market (2019 to 2027) - COVID-19 Impact and Global Analysis

DUBLIN, July 22, 2020 /PRNewswire/ -- The "Viral Vector & Plasmid DNA Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product; Application, and Geography" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global viral vector & plasmid DNA manufacturing market is expected to reach US$ US$ 2, 247.7 million by 2027 from US$ 459.4 million in 2019. The market is estimated to grow with a CAGR of 22.1% from 2020 to 2027.

Driving factors such as growing awareness of gene therapy, increasing prevalence of genetic disorders and infectious diseases across the world are expected to upsurge the market growth. Additionally, growth in the global healthcare market is likely to have a positive impact on the market in coming years. However the high cost associated with gene therapy is the major factor hindering the market growth.

Gene therapies offer an effective way for the treatment of genetic diseases, the acceptance and awareness of gene therapy continues to grow, especially in developed regions. The increase in awareness of gene therapies leads to market entry of new and established players for manufacturing various gene therapy technologies. For instance, according to a study published by Alliance for Regenerative Medicine in 2018, the number of gene therapy-related clinical trials witnessed growth of an estimated 18.0% compared to the previous year across the world. This growth in the number of clinical trials indicates rise in awareness and massive investments.

Established companies, healthcare organizations, and research institutes are focusing on spreading awareness related to gene therapies as they offer a modern way of disease treatment. For instance, in 2018, Alliance for Regenerative Medicine announced the launch of a new foundation to promote comprehensive understanding and acceptance of gene therapies. This newly formed organization will work to grow public awareness and benefits of certain gene therapy-based aspects such as cell therapy, tissue-engineering, gene editing, and organ regeneration.

The global viral vector & plasmid DNA manufacturing market is segmented by product and application. Based on product, the viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the larger share of the market in 2019 andis anticipated to register the higher CAGR during the forecast period. Based on application, the viral vector & plasmid DNA manufacturing market has been segmented into cancer, inherited disorders, viral infections, and others. The cancer segment held the largest share of the market in 2019 and the same segment is estimated to register the highest CAGR in the market during the forecast period.

National Institutes of Health, World Health Organization (WHO), European Medical Association, Centers for Disease Control and Prevention, Canada Foundation of Innovation, Contract Research Organizations, and Dubai Health Authority are some of the essential secondary sources included in the report.

Reasons to Buy

    --  Save and reduce time carrying out entry-level research by identifying
        the growth, size, leading players and segments in the viral vector and
        plasmid DNA manufacturing market.
    --  Highlights key business priorities in order to assist companies to
        realign their business strategies.
    --  The key findings and recommendations highlight crucial progressive
        industry trends in the global viral vector and plasmid DNA manufacturing
        market, thereby allowing players across the value chain to develop
        effective long-term strategies.
    --  Develop/modify business expansion plans by using substantial growth
        offering developed and emerging markets.
    --  Scrutinize in-depth global market trends and outlook coupled with the
        factors driving the market, as well as those hindering it.
    --  Enhance the decision-making process by understanding the strategies that
        underpin security interest with respect to client products,
        segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction

2. Viral Vector and Plasmid DNA Manufacturing Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Viral Vector and Plasmid DNA Manufacturing - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East and Africa (MEA) - PEST Analysis
4.2.5 South and Central America (SCAM) - PEST Analysis
4.3 Expert Opinion

5. Viral Vector and Plasmid DNA Manufacturing Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Awareness of Gene Therapy
5.1.2 Increasing Prevalence of Genetic Disorders and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost Associated with Gene Therapies
5.3 Market Opportunities
5.3.1 Increasing Funding for Gene Therapies
5.4 Future Trends
5.4.1 Integration of Advanced Computing Technologies
5.5 Impact Analysis

6. Viral Vector and Plasmid DNA Manufacturing Market - Global Analysis
6.1 Global Viral Vector and Plasmid DNA Manufacturing Market Revenue Forecast And Analysis
6.2 Global Viral Vector and Plasmid DNA Manufacturing Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Viral Vector and Plasmid DNA Manufacturing Market- By Product
7.1 Overview
7.2 Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)
7.3 Viral Vectors
7.3.1 Overview
7.3.2 Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Non-Viral Vectors
7.4.1 Overview
7.4.2 Non-Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)

8. Viral Vector and Plasmid DNA Manufacturing Market Analysis By Application
8.1 Overview
8.2 Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)
8.3 Cancer
8.3.1 Overview
8.3.2 Cancer: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Inherited Disorders
8.4.1 Overview
8.4.2 Inherited Disorders: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Viral Infections
8.5.1 Overview
8.5.2 Viral-Infections: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)

9. Viral Vector and Plasmid DNA Manufacturing Market - Geographic Analysis
9.1 North America: Viral Vector and Plasmid DNA Manufacturing Market
9.2 Europe: Viral Vector and Plasmid DNA Manufacturing Market
9.3 Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market
9.4 Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market
9.5 South and Central America: Viral Vector and Plasmid DNA Manufacturing Market


10. Impact of COVID-19 Pandemic on Global Viral Vector and Plasmid DNA Manufacturing Market
10.1 North America: Impact assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

11. Viral Vector and Plasma DNA Manufacturing Market - Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview

12. Company Profiles
12.1 Sanofi
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 FUJIFILM Diosynth Biotechnologies
12.3 BRAMMER BIO (Thermo Fisher Scientific Inc.)
12.4 Cell and Gene Therapy Catapult
12.5 Cobra Biologics
12.6 FinVector
12.7 Kaneka Eurogentec S.A.
12.8 MassBiologics
12.9 Spark Therapeutics, Inc.
12.10 UniQure N.V.

13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/t9wdwg

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-viral-vector--plasmid-dna-manufacturing-market-2019-to-2027---covid-19-impact-and-global-analysis-301097985.html

SOURCE Research and Markets